References
- Yumru M, Savas HA, Kurt E, Kaya MC, Selek S, Savas E, et al. Atypical antipsychotics related metabolic syndrome in bipolar patients. J Affect Disord 2007; 98(3): 247–52.
- Morriss R, Mohammed FA. Metabolism, lifestyle and bipolar affective disorder. J Psychopharmacol 2005; 19(Suppl. 6): S94–S101.
- Fagiolini A, Frank E, Scott JA, Turkin S, Kupfer DJ. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord 2005; (7): 424–30.
- Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004; 70(1): 1–17.
- Eker ÖD, Eker Ç. Metabolic side effects of lithium. Psikiyatride Güncel Yaklaşımlar—Current Approaches in Psychiatry 2010; 2(1): 2651. (Turkish).
- Vestergaard P, Poulstrup I, Schou M. Prospective studies on a lithium cohort. 3. Tremor, weight gain, diarrhea, psychological complaints. Acta Psychiatr Scand 1988; 78(4): 434–41.
- Yumru M, E Savas E, Gergerlioglu HS, Basarali K, Kalenderoglu K, Savas HA, Buyukbas S. The relationship of metabolic syndrome, serum leptin levels and treatment in bipolar disorder. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology 2008; 18(2): 79–83. (Turkish).
- Sanisoglu SY, Oktenli C, Hasimi A, Yokusoglu M, Ugurlu M. Prevalence of metabolic syndrome-related disorders in a large adult population in Turkey. BMC Public Health 2006; 6:92.
- Cardenas J, Frye MA, Marusak SL, Levander EM, Chirichigno JW, Lewis S, et al. Modal subcomponents of metabolic syndrome in patients with bipolar disorder. J Affect Disord 2008; 106(1–2): 91–7.
- Correll CU, Frederickson AM, Kane JM, Manu P. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry 2006; 67(4): 575–83.
- Chang HH, Chou CH, Chen PS, Gean PW, Huang HC, Lin CY, et al. High prevalence of metabolic disturbances in patients with bipolar disorder in Taiwan. J Affect Disord 2009; 117(1–2): 124–9.
- Teixeira PJ, Rocha FL. The prevalence of metabolic syndrome among psychiatric inpatients in Brazil. Rev Bras Psiquiatr 2007; 29(4): 330–6.
- Shah A, Shen N, El-Mallakh RS. Weight gain occurs after onset of bipolar illness in overweight bipolar patients. Ann Clin Psychiatry 2006; 18(4): 239–41.
- Simon GE, Von Korff M, Saunders K, Miglioretti DL, Crane PK, van Belle G, et al. Association between obesity and psychiatric disorders in the US adult population. Arch Gen Psychiatry 2006; 63(7): 824–30.
- McElroy SL, Frye MA, Suppes T, Dhavale D, Keck PE Jr, Leverich GS, et al. Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry 2002; 63(3): 207–13.
- Dinesen H, Gram L, Andersen T, Dam M. Weight gain during treatment with valproate. Acta Neurol Scand 1984; 70(2): 65–9.
- Pylvänen V, Knip M, Pakarinen A, Kotila M, Turkka J, Isojärvi JI. Serum insulin and leptin levels in valproate-associated obesity. Epilepsia 2002; 43(5): 514–7.
- Vestergaard P, Schou M. Does long-term lithium treatment induce diabetes mellitus? Neuropsychobiology 1987; 17(3): 130–2.
- Kesebir S, Baykaran B, Toprak B, Tezcan A E. Gender specific metabolic adverse effects in bipolar patients: A comparison between lithium, quetiapine and olanzapine. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology 2011; 21(Suppl.2): S33. (Turkish).